X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Novartis with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs MYLAN (US) - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 NOVARTIS   MYLAN
EQUITY SHARE DATA
    NOVARTIS
Mar-16
MYLAN
Dec-14
NOVARTIS/
MYLAN
5-Yr Chart
Click to enlarge
High Rs9823,861-   
Low Rs5562,721-   
Sales per share (Unadj.) Rs252.91,321.7-  
Earnings per share (Unadj.) Rs62.1159.2-  
Cash flow per share (Unadj.) Rs63.3256.3-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.6657.0-  
Shares outstanding (eoy) m31.96378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x3.02.5 122.1%   
Avg P/E ratio x12.420.7 59.9%  
P/CF ratio (eoy) x12.212.8 94.6%  
Price / Book Value ratio x2.15.0 42.2%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,5801,245,149 2.0%   
No. of employees `0000.825.0 3.0%   
Total wages/salary Rs m1,8010-   
Avg. sales/employee Rs Th10,748.920,004.1 53.7%   
Avg. wages/employee Rs Th2,395.20-   
Avg. net profit/employee Rs Th2,641.12,409.8 109.6%   
INCOME DATA
Net Sales Rs m8,083500,102 1.6%  
Other income Rs m829-2,915 -28.5%   
Total revenues Rs m8,913497,187 1.8%   
Gross profit Rs m234124,378 0.2%  
Depreciation Rs m3736,730 0.1%   
Interest Rs m221,572 0.0%   
Profit before tax Rs m1,02563,161 1.6%   
Minority Interest Rs m0-259 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m7522,656 28.3%   
Profit after tax Rs m1,98660,245 3.3%  
Gross profit margin %2.924.9 11.6%  
Effective tax rate %73.44.2 1,744.5%   
Net profit margin %24.612.0 204.0%  
BALANCE SHEET DATA
Current assets Rs m12,678439,655 2.9%   
Current liabilities Rs m2,433343,723 0.7%   
Net working cap to sales %126.719.2 660.7%  
Current ratio x5.21.3 407.4%  
Inventory Days Days3378 41.9%  
Debtors Days Days22107 21.0%  
Net fixed assets Rs m69115,697 0.1%   
Share capital Rs m16017,685 0.9%   
"Free" reserves Rs m11,4600-   
Net worth Rs m11,621248,600 4.7%   
Long term debt Rs m0371,384 0.0%   
Total assets Rs m14,4001,001,337 1.4%  
Interest coverage x570.53.9 14,524.2%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.60.5 112.4%   
Return on assets %13.88.2 169.0%  
Return on equity %17.124.2 70.5%  
Return on capital %23.613.6 173.0%  
Exports to sales %0.70-   
Imports to sales %18.60-   
Net fx Rs m-1,6350-   
CASH FLOW
From Operations Rs m2,53165,739 3.8%  
From Investments Rs m-8,270-51,843 16.0%  
From Financial Activity Rs m-386-17,322 2.2%  
Net Cashflow Rs m-6,125-3,427 178.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.78 Rs / USD

Compare NOVARTIS With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare NOVARTIS With: AJANTA PHARMA  SUN PHARMA  ORCHID PHARMA LTD  UNICHEM LAB  AUROBINDO PHARMA  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 21, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS